Development of a key performance indicator for breast cancer in Queensland, Australia
Rattachement africain : au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
PURPOSE: Using population-based data for women diagnosed with stage I-III breast cancer, our aim was to examine the impact of time to treatment completion on survival and to identify factors associated with treatment delay. METHODS: This retrospective study used clinical and treatment data from the Queensland Oncology Repository. Time from diagnosis to completing surgery, chemotherapy and radiation therapy identified a cut-off of 37 weeks as the optimal threshold for completing treatment. Logistic regression was used to identify factors associated with the likelihood of completing treatment > 37 weeks. Overall (OS) and breast cancer-specific survival (BCSS) were examined using Cox proportional hazards models. RESULTS: Of 8279 women with stage I-III breast cancer, 31.9% completed treatment > 37 weeks. Apart from several clinical factors, being Indigenous (p = 0.002), living in a disadvantaged area (p = 0.003) and receiving ≥ two treatment modalities within the public sector (p < 0.001) were associated with an increased likelihood of completing treatment > 37 weeks. The risk of death from any cause was about 40% higher for women whose treatment went beyond 37 weeks (HR 1.37, 95%CI 1.16-1.61), a similar result was observed for BCSS. Using the surgery + chemotherapy + radiation pathway, a delay of > 6.9 weeks from surgery to starting chemotherapy was significantly associated with poorer survival (p = 0.001). CONCLUSIONS: Several sociodemographic and system-related factors were associated with a greater likelihood of treatment completion > 37 weeks. We are proposing a key performance indicator for the management of early breast cancer where a facility should have > 90% of patients with a time from surgery to adjuvant chemotherapy < 6.9 weeks.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Development of a key performance indicator for breast cancer in Queensland, Australia
- Date Crossref
- 09/11/2022
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The University of Queensland Translational Research Institute pays non établi dans la noticeUniversité ou école supérieure
-
Princess Alexandra Hospital Division of Cancer Services pays non établi dans la noticeÉtablissement de santé
-
Metro South Health pays non établi dans la noticeÉtablissement de santé
-
Sunshine Coast University Hospital Sunshine Coast Hospital and Health Service pays non établi dans la noticeÉtablissement de santé
-
Translational Research Institute pays non établi dans la noticeStructure de recherche
-
Metro South Hospital and Health Service Queensland Cancer Control Safety and Quality Partnership pays non établi dans la noticeÉtablissement de santé
Translational Research Institute — The University of Queensland, Division of Cancer Services — Princess Alexandra Hospital et Metro South Health, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.